- Home
- GEVO vs ALDX Comparison
GEVO vs ALDX Comparison
Compare GEVO & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEVO
- ALDX
- Stock Information
- Founded
- GEVO 2005
- ALDX 2004
- Country
- GEVO United States
- ALDX United States
- Employees
- GEVO N/A
- ALDX N/A
- Industry
- GEVO Major Chemicals
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- GEVO Industrials
- ALDX Health Care
- Exchange
- GEVO Nasdaq
- ALDX Nasdaq
- Market Cap
- GEVO 285.1M
- ALDX 133.7M
- IPO Year
- GEVO 2011
- ALDX 2014
- Fundamental
- Price
- GEVO $1.14
- ALDX $2.16
- Analyst Decision
- GEVO Buy
- ALDX Strong Buy
- Analyst Count
- GEVO 2
- ALDX 2
- Target Price
- GEVO $7.58
- ALDX $9.50
- AVG Volume (30 Days)
- GEVO 2.4M
- ALDX 1.5M
- Earning Date
- GEVO 05-13-2025
- ALDX 05-20-2025
- Dividend Yield
- GEVO N/A
- ALDX N/A
- EPS Growth
- GEVO N/A
- ALDX N/A
- EPS
- GEVO N/A
- ALDX N/A
- Revenue
- GEVO $16,915,000.00
- ALDX N/A
- Revenue This Year
- GEVO $617.82
- ALDX N/A
- Revenue Next Year
- GEVO $84.22
- ALDX N/A
- P/E Ratio
- GEVO N/A
- ALDX N/A
- Revenue Growth
- GEVO N/A
- ALDX N/A
- 52 Week Low
- GEVO $0.48
- ALDX $1.14
- 52 Week High
- GEVO $3.39
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- GEVO 49.70
- ALDX 34.82
- Support Level
- GEVO $1.00
- ALDX $1.90
- Resistance Level
- GEVO $1.14
- ALDX $2.89
- Average True Range (ATR)
- GEVO 0.08
- ALDX 0.23
- MACD
- GEVO 0.00
- ALDX 0.10
- Stochastic Oscillator
- GEVO 60.87
- ALDX 26.26
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.